The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer

Video

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.

Related Videos
Rebecca A. Shatsky, MD, an expert on breast cancer
Experts on breast cancer
Expert on breast cancer
Experts on breast cancer
Expert on breast cancer
Experts on breast cancer
Related Content